Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis
Cancer Research and Treatment. 2016;48(3):1110-1119 
Phase II Clinical Trial Data with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib (OSI-774) in Non–Small-Cell Lung Cancer
Clinical Lung Cancer. 2004;6:S20-S23
Epidermal growth factor receptor mutations and their correlation with epidermal growth factor receptor-tyrosine kinase inhibitor therapy and association with the characteristics of patients with non-small-cell lung cancer: A meta-analysis
Thoracic Cancer. 2011;2(3):101-108
THE EGFR
MUTATION PATTERN AFTER EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITORS THERAPY IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER HARBOURING ACTIVATING UNCOMMON EGFR
MUTATIONS
Respirology. 2018;23:286-286
Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non–small-cell Lung Cancer
Clinical Lung Cancer. 2020;21(6):e647-e653
Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer
Annals of Oncology. 2006;17:ii46-ii48
Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: Chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib
Lung Cancer. 2013;82(2):305-312
Epidermal growth factor receptor (EGFR) in non small cell lung cancer (NSCLC)
Lung Cancer. 1994;11:2
First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR Mutation; Positive Non-small Cell Lung Cancer Patients
Journal of Thoracic Oncology. 2008;3(6):S143-S145
American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
Yearbook of Oncology. 2011;2011:220-221